Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns

2026-02-13 21:33:47

The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.